Finance

Lists
Why is KROS down 2,03%?
Dive Deeper
KROS:NASDAQ
Keros Therapeutics Inc
9,17 $
-2,03%
(-0,19) 1D
9,17 $
0,00% (0,00)
After hours
Closed: 9 նոյ, 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KROS...
Open
9,50 $
High
9,87 $
Low
9,10 $
Mkt. cap
181,82 մլն
Avg. vol.
164,30 հզր
Volume
0,00
52-wk high
22,55 $
52-wk low
9,10 $
EPS
-2,83 $
Beta
1,13
Shares outstanding
19,62 մլն
No. of employees
87
Open
9,50 $
High
9,87 $
Low
9,10 $
Mkt. cap
181,82 մլն
Avg. vol.
164,30 հզր
Volume
0,00
52-wk high
22,55 $
52-wk low
9,10 $
EPS
-2,83 $
Beta
1,13
Shares outstanding
19,62 մլն
No. of employees
87
News stories
From web sources and news partners
About Keros Therapeutics Inc
CEO-
Employees87
Founded2015
HeadquartersLexington, Մասսաչուսեթս, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Websitekerostx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KROS in the past 3 months
Buy
Buy
2
Hold
2
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KROS in the last 3 months.
Highest
Current 9,17 $
20,00 $ (+118,10%)
Average
17,75 $ (+93,57%)
Lowest
16,00 $ (+74,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yun Zhong
Wedbush
Hold
Maintained
16,00 $
+74,5%
11/09/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
20,00 $
+118,1%
11/06/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
18,00 $
+96,3%
09/02/2026
Jason Zemansky
Bank of America Securities
Hold
Reiterated
17,00 $
+85,4%
08/11/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
08/04/2026
Thomas Smith
Leerink Partners
Buy
Maintained
23,00 $
+150,8%
08/04/2026
Nicholas Lorusso
TD Cowen
Hold
Reiterated
-
-
08/04/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/15/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
27,00 $
+194,4%
03/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
30,00 $
+227,2%
03/06/2026
Tiago Fauth
Raymond James
Buy
Maintained
20,00 $
+118,1%
03/05/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
385,00 հզր
367,00 հզր
-
40,01 մլն
Cost of goods sold
17,81 մլն
16,10 մլն
22,33 մլն
-
Cost of revenue
17,81 մլն
16,10 մլն
22,33 մլն
-
Research and development expenses
-
-
-
20,49 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,74 մլն
10,15 մլն
8,61 մլն
6,70 մլն
Operating expense
11,74 մլն
10,15 մլն
8,61 մլն
27,19 մլն
Total operating expenses
29,56 մլն
26,24 մլն
30,94 մլն
27,19 մլն
Operating income
-29,17 մլն
-25,88 մլն
-30,94 մլն
12,82 մլն
Other non operating income
-539,00 հզր
-
-60,00 հզր
-168,00 հզր
EBT including unusual items
-24,98 մլն
-23,71 մլն
-28,71 մլն
14,92 մլն
EBT excluding unusual items
-24,88 մլն
-23,71 մլն
-28,71 մլն
14,92 մլն
Income tax expense
-1,51 մլն
-
-
772,00 հզր
Effective tax rate
6,06%
-
-
5,17%
Other operating expenses
-
-
-
-
Net income
-23,46 մլն
-23,71 մլն
-28,71 մլն
14,15 մլն
Net profit margin
-6 093,77%
-6 459,95%
-
35,37%
Earnings per share
-0,86
-1,21
-1,45
0,70
Interest and investment income
4,02 մլն
2,34 մլն
2,29 մլն
2,28 մլն
Interest expense
-
-
-
-
Net interest expenses
4,02 մլն
2,34 մլն
2,29 մլն
2,28 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-28,77 մլն
-25,47 մլն
-30,54 մլն
13,20 մլն
Gain or loss from assets sale
1,00 հզր
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps